Free Access
Med Sci (Paris)
Volume 23, Number 3, Mars 2007
Page(s) 279 - 284
Section M/S revues
Published online 15 March 2007
  1. Banchereau J, Brière F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18 : 767–811. [Google Scholar]
  2. Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen processing machines. Cell 2001; 106 : 255–8. [Google Scholar]
  3. Mempel TR, Henrickson SE, Von Andrian UH. T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature 2004; 427 : 154–9. [Google Scholar]
  4. Caux C, Vanbervliet B, Massacrier C, et al. B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells. J Exp Med 1994; 180 : 1841–47. [Google Scholar]
  5. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392 : 245–52. [Google Scholar]
  6. Sallusto F, Schaerli P, Loetscher P, et al. Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation. Eur J Immunol 1998; 28 : 2760–9. [Google Scholar]
  7. Lanzavecchia A, Sallusto F. Regulation of T cell immunity by dendritic cells. Cell 2001; 106 : 263–6. [Google Scholar]
  8. Gilboa E, Nair SK, Lyerly HK. Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol Immunother 1998; 46 : 82–7. [Google Scholar]
  9. Lu W, Arraes LC, Ferreira WT, Andrieu JM. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med 2004; 10 : 1359–65. [Google Scholar]
  10. Banchereau J, Palucka AK, Dhodapkar M, et al. Immune and clinical responses in patients with metastatic melanoma to CD34+ progenitor-derived dendritic cell vaccine. Cancer Res 2001; 61 : 6451–58. [Google Scholar]
  11. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4 : 328–32. [Google Scholar]
  12. Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996; 184 : 465–72. [Google Scholar]
  13. Heiser A, Coleman D, Dannull J, et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 2002; 109 : 409–17. [Google Scholar]
  14. Su Z, Dannull J, Heiser A, et al. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res 2003; 63 : 2127–33. [Google Scholar]
  15. Pardoll DM, Topalian SL. The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol 1998; 5 : 588–94. [Google Scholar]
  16. Nair SK, Boczkowski D, Morse M, et al. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat Biotechnol 1998; 16 : 364–9. [Google Scholar]
  17. Su Z, Dannull J, Yang BK, et al. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J Immunol 2005; 174 : 3798–807. [Google Scholar]
  18. Zhao Y, Boczkowski D, Nair SK, Gilboa E. Inhibition of invariant chain expression in dendritic cells presenting endogenous antigens stimulates CD4+ T-cell responses and tumor immunity. Blood. 2003; 102 : 4137–42. [Google Scholar]
  19. Kavanagh DG, Kaufmann DE, Sunderji S, et al. Expansion of HIV-specific CD4+ and CD8+ T cells by dendritic cells transfected with mRNA encoding cytoplasm- or lysosome-targeted Nef. Blood 2006; 107 : 1963–9. [Google Scholar]
  20. Van Gulck ER, Ponsaerts P, Heyndrickx L, et al. Efficient stimulation of HIV-1-specific T cells using dendritic cells electroporated with mRNA encoding autologous HIV-1 Gag and Env proteins. Blood 2006; 107 : 1818–27. [Google Scholar]
  21. Janssen EM, Lemmens EE, Wolfe T, et al. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 2003; 421 : 852–6. [Google Scholar]
  22. Nopora A, Brocker T. Bcl-2 controls dendritic cell longevity in vivo. J Immunol 2002; 169 : 3006–14. [Google Scholar]
  23. Peng S, Kim TW, Lee JH, et al. Vaccination with dendritic cells transfected with BAK and BAX siRNA enhances antigen-specific immune responses by prolonging dendritic cell life. Hum Gen Ther 2005; 16 : 584–93. [Google Scholar]
  24. Cella M, Scheidegger D, Palmer-Lehmann K, et al. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 1996; 184 : 747–52. [Google Scholar]
  25. Macleod M, Kwakkenbos MJ, Crawford A, et al. CD4 memory T cells survive and proliferate but fail to differentiate in the absence of CD40. J Exp Med 2006; 203 : 897–906. [Google Scholar]
  26. Morse MA, Coleman RE, Akabani G, et al. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res 1999; 59 : 56–8. [Google Scholar]
  27. Okada N, Mori N, Koretomo R, et al. Augmentation of the migratory ability of DC-based vaccine into regional lymph nodes by efficient CCR7 gene transduction. Gene Ther 2005; 12 : 129–39. [Google Scholar]
  28. Caruso DA, Orme LM, Neale AM, et al. Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer. Neuro Oncol 2004; 6 : 236–46. [Google Scholar]
  29. Caruso DA, Orme LM, Amor GM, et al. Results of a phase I study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children with Stage 4 neuroblastoma. Cancer 2005; 103 : 1280–91. [Google Scholar]
  30. Morse MA, Nair SK, Mosca PJ, et al. Immunotherapy with autologous human dendritic cells transfected with carcinoembryonic antigen mRNA. Cancer Invest 2003; 21 : 341–9. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.